Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.70 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.70 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.70 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.70 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.70 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.70 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.70 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.70 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.70 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.70 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ARG1 | P05089 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9601914 | 1.00 | MEN1 (0.70) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL5058500 | 1.00 | MEN1 (0.70) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL5058328 | 1.00 | MEN1 (0.70) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL5489971 | 0.86 | MEN1 (0.53) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL5490113 | 0.84 | MEN1 (0.51) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL14521431 | 0.84 | ARG1 (0.51) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL9602175 | 0.82 | ARG1 (0.58) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL9602262 | 0.82 | ARG1 (0.58) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL9602274 | 0.82 | ARG1 (0.58) | MEN1KMT2ACYP1A2ALOX15CYP2C19 | |
| Selfotel SCHEMBL120234 | 0.82 | MEN1 (1.00) | MEN1KMT2ACYP1A2ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1077690-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | Neurochem, Inc. (CA) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059571-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | NEUROCHEM, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5217963-A | Antiischemic, antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| US-5057506-A | Anticonvulsants, antispasmodic and antischemic agents | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0203891-B1 | CERTAIN PHOSPHONIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-05-15 | — | — | EP | disclosed |
| US-4906621-A | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | CIBA-GEIGY CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| US-4898854-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0203891-A2 | Certain phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | MEN1 1863/4885KMT2A 3285/4885CYP1A2 4190/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | MEN1 3689/4885KMT2A 4378/4885CYP1A2 4396/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | MEN1 3711/4885KMT2A 4400/4885CYP1A2 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.